LUNGevity: Lung Cancer Stigma Community Based Participatory Research
Conditions: Lung Cancer Interventions: Behavioral: Ultra-brief mindfulness intervention video; Behavioral: Forgiveness video; Behavioral: ACT values video Sponsors: Rutgers, The State University of New Jersey Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 29, 2024 Category: Research Source Type: clinical trials
A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors
Conditions: Neoplasms; Non-small-cell Lung Cancer; Melanoma; Squamous Cell Carcinoma of the Head and Neck; Renal Cell Carcinoma; Urothelial Carcinoma; Colorectal Carcinoma; Ovarian Carcinoma Interventions: Drug: PF-07820435; Biological: Sasanlimab Sponsors: Pfizer Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 29, 2024 Category: Research Source Type: clinical trials
Efficacy and Safety of Single-port Surgical Robot System in Thoraic Surgery
Conditions: Lung Cancer Interventions: Procedure: Surgical robot system Sponsors: The First Affiliated Hospital of Guangzhou Medical University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 29, 2024 Category: Research Source Type: clinical trials
Centralized Screening Unit (CSU) at Montefiore-Einstein
Conditions: Lung Cancer Interventions: Other: Centralized Screening Unit Implementation Sponsors: Albert Einstein College of Medicine; American Cancer Society, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 29, 2024 Category: Research Source Type: clinical trials
Deep Learning Model Predicts Pathological Complete Response of Lung Cancer Following Neoadjuvant Immunochemotherapy
Conditions: Deep Learning Model; Pathological Complete Response; Non-small Cell Lung Cancer; Neoadjuvant Chemoimmunotherapy Interventions: Diagnostic Test: No interventions Sponsors: Wuhan Union Hospital, China Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 29, 2024 Category: Research Source Type: clinical trials
Recombinant Human Endostatin Combined With Envafolimab and Synchronal Radiochemotherapy
Conditions: Locally Advanced Squamous Non-small Cell Lung Cancer Interventions: Drug: Recombinant Human Endostatin Injection Sponsors: The First Affiliated Hospital of Xinxiang Medical College Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 28, 2024 Category: Research Source Type: clinical trials
Neoadjuvant Therapy With Iruplinalkib for Potentially Resectable ALK Positive NSCLC: A Single Arm, Exploratory Trial
Conditions: Potentially Resectable ALK Positive Non-Small Cell Lung Cancer Interventions: Drug: Iruplinalkib; Procedure: surgery Sponsors: Shanghai Pulmonary Hospital, Shanghai, China Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 28, 2024 Category: Research Source Type: clinical trials
Efficacy and Safety Evaluation of PLB1004 in Patients With Non-squamous NSCLC Harboring EGFR Exon 20 Insertion.
Conditions: Non-Small-Cell Lung Cancer Interventions: Drug: PLB1004; Drug: Pemetrexed+ （carboplatin or Cisplatin）with or without Sintilimab Sponsors: Avistone Biotechnology Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 28, 2024 Category: Research Source Type: clinical trials
AI Determine Malignancy of GGO on Chest CT
Conditions: Lung Nodules, Early Lung Cancer, Artificial Intelligence, Chest CT, Minimally Invasive Surgery, Lung Image Analysis Software Interventions: Diagnostic Test: AI computer-aided detection software Sponsors: Chung Shan Medical University Enrolling by invitation (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 28, 2024 Category: Research Source Type: clinical trials
A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer Which Could Not Be Controlled
Conditions: Non-Small Cell Lung Carcinoma Interventions: Drug: Lorlatinib Sponsors: Pfizer Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 28, 2024 Category: Research Source Type: clinical trials
Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Advanced Small Cell Lung Cancer
Conditions: Small Cell Lung Cancer; Neuroendocrine Cancer Interventions: Biological: ZG006 Sponsors: Suzhou Zelgen Biopharmaceuticals Co.,Ltd Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 28, 2024 Category: Research Source Type: clinical trials
An Exploratory Clinical Study to Evaluate the Safety and Efficacy of NK Cells (Combined With Standard Therapy) in the Treatment of Solid Tumor Patients
Conditions: Solid Tumors (Pancreatic Cancer, Esophageal Cancer, Gastric Cancer, Cholangiocarcinoma, Lung Cancer and Ovarian Cancer) Interventions: Drug: Allogeneic NK （CCT-ANK-11) Sponsors: Escure Biotechnology Corp; Beijing Kejing Biotechnology Corp. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 28, 2024 Category: Research Source Type: clinical trials
An International, Multicentre, Open-label Randomised Phase III Trial to Evaluate the Benefit of Adding Adjuvant Durvalumab After Neoadjuvant Chemotherapy Plus Durvalumab in Patients With Stage IIB-IIIB (N2) Resectable NSCLC
Conditions: Non Small Cell Lung Cancer Interventions: Drug: Adjuvant durvalumab Sponsors: ETOP IBCSG Partners Foundation; AstraZeneca AG Switzerland Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 28, 2024 Category: Research Source Type: clinical trials
Medical Access Program for Datopotamab Deruxtecan in NSCLC Patients
Conditions: Advanced Nonsquamous Non-Small Cell Lung Cancer; Metastatic Nonsquamous Non-Small Cell Lung Cancer Interventions: Drug: Datopotamab deruxtecan Sponsors: Daiichi Sankyo; AstraZeneca Available (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 28, 2024 Category: Research Source Type: clinical trials
A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer.
Conditions: Non Small Cell Lung Cancer Interventions: Drug: Adjuvant durvalumab Sponsors: ETOP IBCSG Partners Foundation; AstraZeneca AG Switzerland Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 28, 2024 Category: Research Source Type: clinical trials
